Your browser doesn't support javascript.
loading
Prophylactic Oral Dextrose Gel and Neurosensory Impairment at 2-Year Follow-up of Participants in the hPOD Randomized Trial.
Edwards, Taygen; Alsweiler, Jane M; Crowther, Caroline A; Edlin, Richard; Gamble, Greg D; Hegarty, Joanne E; Lin, Luling; McKinlay, Christopher J D; Rogers, Jenny A; Thompson, Benjamin; Wouldes, Trecia A; Harding, Jane E.
Afiliação
  • Edwards T; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Alsweiler JM; Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
  • Crowther CA; Newborn Services, Auckland City Hospital, Auckland, New Zealand.
  • Edlin R; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Gamble GD; Health Systems, School of Population Health, University of Auckland, Auckland, New Zealand.
  • Hegarty JE; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Lin L; Newborn Services, Auckland City Hospital, Auckland, New Zealand.
  • McKinlay CJD; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Rogers JA; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Thompson B; Kidz First Neonatal Care, Counties Manukau Health, Auckland, New Zealand.
  • Wouldes TA; Liggins Institute, University of Auckland, Auckland, New Zealand.
  • Harding JE; School of Optometry and Vision Science, Waterloo, Ontario, Canada.
JAMA ; 327(12): 1149-1157, 2022 03 22.
Article em En | MEDLINE | ID: mdl-35315885
Importance: Prophylactic oral dextrose gel reduces neonatal hypoglycemia, but later benefits or harms remain unclear. Objective: To assess the effects on later development of prophylactic dextrose gel for infants born at risk of neonatal hypoglycemia. Design, Setting, and Participants: Prospective follow-up of a multicenter randomized clinical trial conducted in 18 Australian and New Zealand hospitals from January 2015 to May 2019. Participants were late preterm or term at-risk infants; those randomized in 9 New Zealand centers (n = 1359) were included and followed up between January 2017 and July 2021. Interventions: Infants were randomized to prophylactic 40% dextrose (n = 681) or placebo (n = 678) gel, 0.5 mL/kg, massaged into the buccal mucosa 1 hour after birth. Main Outcomes and Measures: The primary outcome of this follow-up study was neurosensory impairment at 2 years' corrected age. There were 44 secondary outcomes, including cognitive, language, and motor composite Bayley-III scores (mean [SD], 100 [15]; higher scores indicate better performance). Results: Of eligible infants, 1197 (91%) were assessed (581 females [49%]). Neurosensory impairment was not significantly different between the dextrose and placebo gel groups (20.8% vs 18.7%; unadjusted risk difference [RD], 2.09% [95% CI, -2.43% to 6.60%]; adjusted risk ratio [aRR], 1.13 [95% CI, 0.90 to 1.41]). The risk of cognitive and language delay was not significantly different between the dextrose and placebo groups (cognitive: 7.6% vs 5.3%; RD, 2.32% [95% CI, -0.46% to 5.11%]; aRR, 1.40 [95% CI, 0.91 to 2.17]; language: 17.0% vs 14.7%; RD, 2.35% [95% CI, -1.80% to 6.50%]; aRR, 1.19 [95% CI, 0.92 to 1.54]). However, the dextrose gel group had a significantly higher risk of motor delay (2.5% vs 0.7%; RD, 1.81% [95% CI, 0.40% to 3.23%]; aRR, 3.79 [95% CI, 1.27 to 11.32]) and significantly lower composite scores for cognitive (adjusted mean difference [aMD], -1.30 [95% CI, -2.55 to -0.05]), language (aMD, -2.16 [95% CI, -3.86 to -0.46]), and motor (aMD, -1.40 [95% CI, -2.60 to -0.20]) performance. There were no significant differences between groups in the other 27 secondary outcomes. Conclusions and Relevance: Among late preterm and term infants born at risk of neonatal hypoglycemia, prophylactic oral 40% dextrose gel at 1 hour of age, compared with placebo, resulted in no significant difference in the risk of neurosensory impairment at 2 years' corrected age. However, the study may have been underpowered to detect a small but potentially clinically important increase in risk, and further research including longer-term follow-up is required. Trial Registration: anzctr.org.au Identifier: ACTRN12614001263684.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Sensação / Glucose / Hipoglicemia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Male / Newborn Idioma: En Revista: JAMA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos de Sensação / Glucose / Hipoglicemia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child, preschool / Female / Humans / Male / Newborn Idioma: En Revista: JAMA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Nova Zelândia